Australia signs two more COVID-19 vaccine deals By Reuters

© Reuters. FILE PHOTO: Vials and medical syringe are seen in front of Novavax logo in this illustration

By Renju Jose and Colin Packham

SYDNEY (Reuters) – Australia has agreed to purchase another 50 million doses of two more COVID-19 vaccines, Prime Minister Scott Morrison said on Thursday, as Canberra aims to complete a mass inoculation programme within months.

Australia in September said it had agreed to spend A$1.7 billion ($1.2 billion) to buy 85 million vaccine doses from AstraZeneca (L:) and CSL Ltd (AX:) should the trails prove successful.

But seeking to maximise access to potential vaccines, Australia said on Thursday it had also agreed to purchase two other inoculations.

Australia would buy 40 million doses from Novavax (O:) and 10 million from Pfizer (N:) and BioNTech (F:), Morrison said.

“We aren’t putting all our eggs in one basket,” Morrison told reporters in Sydney.

The deals with Novavax, Pfizer and BioNTech are worth about A$1.5 billion.

The Pfizer-BioNTech vaccine along with AstraZeneca’s and Novavax’s are among the leading candidates in the race to be the first to get regulatory approval in the United States and Europe.

Should trials prove successful, Australia expects to receive the first batches of the AstraZeneca vaccine in early 2021.

Health Minister Greg Hunt said should all go to plan, vaccinations would begin in March.

“The goal and the expectation is that Australians who sought vaccination will be vaccinated within 2021,” Hunt said.

Australia has reported just over 27,600 coronavirus cases and 907 deaths, far fewer than most other developed countries thanks to extensive testing, contact tracing and lockdowns.

Case numbers have slowed to fewer than 10 each day, allowing states and territories to relax social-distancing restrictions.

($1 = 1.3916 Australian dollars)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.